Clinical Trial Update: Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus® [Phase 1]

View source ↗

Summary

A Phase 1 dose–response study comparing a new insulin glargine formulation with Lantus in Type 1 diabetes has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (new formulation) (insulin glargine)
• Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Type 1 Diabetes Mellitus | Phase 1 | Status: COMPLETED